Last reviewed · How we verify
Rabies immune globulin (human)
Rabies immune globulin provides passive immunization by supplying human antibodies that neutralize rabies virus and prevent its progression to the central nervous system.
Rabies immune globulin provides passive immunization by supplying human antibodies that neutralize rabies virus and prevent its progression to the central nervous system. Used for Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies virus exposure.
At a glance
| Generic name | Rabies immune globulin (human) |
|---|---|
| Also known as | IMOGAM® Rabies-HT |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Passive immunizing agent; immunoglobulin |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Immunology; Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This product contains immunoglobulin G (IgG) antibodies derived from human plasma of donors immunized against rabies virus. These antibodies bind to and neutralize rabies virus particles, preventing viral attachment and entry into nerve cells. It is administered as part of post-exposure prophylaxis (PEP) alongside rabies vaccine to provide immediate protection while the vaccine stimulates active immunity.
Approved indications
- Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies virus exposure
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
- Hypersensitivity reactions
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody (PHASE2)
- Washington University WU 409: Immune Responses to Rabies Vaccine. (EARLY_PHASE1)
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Survey of Human Rabies Immune Globulin Safety in Children
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabies immune globulin (human) CI brief — competitive landscape report
- Rabies immune globulin (human) updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI